Bottom line
How much do FHLC and FTXH overlap?
51% of their top holdings overlap by weight. 11 securities appear in both funds' top 25, making up 46.4% of FHLC's assets and 54.2% of FTXH's. They share a meaningful core but differ in the rest of the portfolio.
FHLC holds far more positions (337 vs 51), so it is broader beyond the top names.
Updated Nov 22, 2026
Overlap at a glance
Holdings FHLC and FTXH have in common
| Holding | % of FHLC | % of FTXH | Overlap |
|---|---|---|---|
| Eli Lilly & Co | 13.35% | 7.77% | 7.77% |
| Johnson & Johnson | 8.93% | 6.96% | 6.96% |
| AbbVie Inc | 6.42% | 7.39% | 6.42% |
| Merck & Co Inc | 4.66% | 7.07% | 4.66% |
| Amgen Inc | 3.00% | 3.18% | 3.00% |
| Gilead Sciences Inc | 2.34% | 2.89% | 2.34% |
| Pfizer Inc | 2.06% | 2.97% | 2.06% |
| Bristol-Myers Squibb Co | 1.93% | 6.29% | 1.93% |
| Vertex Pharmaceuticals Inc | 1.76% | 3.41% | 1.76% |
| Regeneron Pharmaceuticals Inc | 1.15% | 2.72% | 1.15% |
| Cardinal Health Inc | 0.78% | 3.53% | 0.78% |
Source: SEC Form N-PORT (periods Jul 31, 2026 / Jun 30, 2026)
Free weekly newsletter
The Fund Letter
Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.
Free. Unsubscribe anytime. We never sell your email.
What each fund holds that the other doesn't
Top-25 holdings that appear in only one of the two funds' top 25.
Only in FHLC
- UnitedHealth Group Inc — 5.44%
- Thermo Fisher Scientific Inc — 3.09%
- Abbott Laboratories — 2.66%
- CVS Health Corp — 1.92%
- Intuitive Surgical Inc — 1.82%
- Danaher Corp — 1.80%
- Stryker Corp — 1.62%
- Medtronic PLC — 1.59%
- McKesson Corp — 1.52%
- Elevance Health Inc — 1.19%
- Cigna Group/The — 1.06%
- Boston Scientific Corp — 1.00%
- HCA Healthcare Inc — 0.91%
- Cencora Inc — 0.83%
Only in FTXH
- Biogen Inc — 3.84%
- Viatris Inc — 3.62%
- United Therapeutics Corp — 2.72%
- Jazz Pharmaceuticals Plc — 2.49%
- Incyte Corp — 2.39%
- Illumina Inc — 1.98%
- Zoetis Inc — 1.87%
- Exelixis Inc — 1.72%
- Charles River Laboratories International Inc — 1.49%
- Medpace Holdings Inc — 1.41%
- Ptc Therapeutics Inc — 1.37%
- Neurocrine Biosciences Inc — 1.37%
- Alkermes Plc — 1.35%
- Halozyme Therapeutics Inc — 1.21%
Asset mix
| Asset type | FHLC | FTXH |
|---|---|---|
| Stocks | 99.7% | 99.9% |
| Cash & short-term funds | 0.2% | 0.1% |
Source: SEC Form N-PORT (periods Jul 31, 2026 / Jun 30, 2026)
Country mix
| Country | FHLC | FTXH |
|---|---|---|
| US | 96.5% | 95.6% |
| IE | 2.2% | 3.8% |
| BM | 0.2% | 0.6% |
| GB | 0.5% | — |
| CA | 0.2% | — |
| CH | 0.1% | — |
| NL | 0.1% | — |
Source: SEC Form N-PORT (periods Jul 31, 2026 / Jun 30, 2026)
Check another pair
FAQ
How much do FHLC and FTXH overlap?
What stocks do FHLC and FTXH have in common?
Should I own both FHLC and FTXH?
Which holds more stocks, FHLC or FTXH?
Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.